BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26501073)

  • 1. JAK-STAT in lymphoproliferative disorders.
    Rabadan R; Inghirami G
    Oncoscience; 2015; 2(9):737-8. PubMed ID: 26501073
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.
    Shouse G; Nikolaenko L
    Curr Hematol Malig Rep; 2019 Dec; 14(6):570-576. PubMed ID: 31741284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.
    Kim BH; Yin CH; Guo Q; Bach EA; Lee H; Sandoval C; Jayabose S; Ulaczyk-Lesanko A; Hall DG; Baeg GH
    Mol Cancer Ther; 2008 Sep; 7(9):2672-80. PubMed ID: 18790749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
    Waldmann TA; Chen J
    Annu Rev Immunol; 2017 Apr; 35():533-550. PubMed ID: 28182501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder.
    Nepomuceno RR; Snow AL; Robert Beatty P; Krams SM; Martinez OM
    Transplantation; 2002 Aug; 74(3):396-402. PubMed ID: 12177620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.
    Soderquist CR; Patel N; Murty VV; Betman S; Aggarwal N; Young KH; Xerri L; Leeman-Neill R; Lewis SK; Green PH; Hsiao S; Mansukhani MM; Hsi ED; de Leval L; Alobeid B; Bhagat G
    Haematologica; 2020 Jul; 105(7):1895-1906. PubMed ID: 31558678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.
    Kuusanmäki H; Dufva O; Parri E; van Adrichem AJ; Rajala H; Majumder MM; Yadav B; Parsons A; Chan WC; Wennerberg K; Mustjoki S; Heckman CA
    Oncotarget; 2017 Nov; 8(57):97516-97527. PubMed ID: 29228628
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Andersson EI; Brück O; Braun T; Mannisto S; Saikko L; Lagström S; Ellonen P; Leppä S; Herling M; Kovanen PE; Mustjoki S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32188095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
    Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
    Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Large Granular Lymphocytic Leukemia and JAK/STAT Signaling Pathway--Review].
    Qiu ZY; Fan Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):254-60. PubMed ID: 26913432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
    Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
    Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
    Derenzini E; Younes A
    Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.
    Quesada AE; Zhang Y; Ptashkin R; Ho C; Horwitz S; Benayed R; Dogan A; Arcila ME
    Breast J; 2021 Apr; 27(4):314-321. PubMed ID: 33660353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences.
    Ott N; Faletti L; Heeg M; Andreani V; Grimbacher B
    J Clin Immunol; 2023 Aug; 43(6):1326-1359. PubMed ID: 37140667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
    Lahera A; López-Nieva P; Alarcón H; Marín-Rubio JL; Cobos-Fernández MÁ; Fernández-Navarro P; Fernández AF; Vela-Martín L; Sastre I; Ruiz-García S; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Br J Haematol; 2023 May; 201(4):718-724. PubMed ID: 36786170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph).
    Butterbach K; Beckmann L; de Sanjosé S; Benavente Y; Becker N; Foretova L; Maynadie M; Cocco P; Staines A; Boffetta P; Brennan P; Nieters A
    Br J Haematol; 2011 May; 153(3):318-33. PubMed ID: 21418178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a non-canonical JAK/STAT signaling pathway in the synthesis of the brain's major ion channels and neurotransmitter receptors.
    Hixson KM; Cogswell M; Brooks-Kayal AR; Russek SJ
    BMC Genomics; 2019 Aug; 20(1):677. PubMed ID: 31455240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
    Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
    Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.